Scarica l'app Stockscreener
35.89
0.64%
0.23
Pre-mercato:
35.46
-0.43
-1.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$35.66
Aprire:
$34.5
Volume 24 ore:
13.83M
Relative Volume:
1.31
Capitalizzazione di mercato:
$14.02B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-4.1111
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+21.70%
1M Prestazione:
+29.57%
6M Prestazione:
+20.03%
1 anno Prestazione:
-24.49%
Intervallo 1D:
$34.42
$37.10
Intervallo di 1 settimana:
$29.81
$37.10
Portata 52W:
$22.28
$47.70
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
35.89 | 13.93B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Biotech Co. Says HHS Infringed Patent With Moderna Vax Deal - Law360
What Analysts Are Saying About Moderna Stock - Benzinga
UBS Lowers Moderna (MRNA) Price Target to $34, Rating Changed to Neutral | MRNA Stock News - GuruFocus
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonald's, Moderna, and More - 24/7 Wall St.
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Bayer sues COVID vaccine makers over mRNA technology - ETPharma.com
My Top 5 Stocks to Buy in Early 2026 - The Motley Fool
Moderna (MRNA) Soars 10.9%: Is Further Upside Left in the Stock? - Nasdaq
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - The Asheville Citizen Times
Bayer Sues Biontech and Pfizer Over Patents for Covid Vaccines - MarketScreener
Bayer Targets Pfizer, Moderna, J&J For Covid Jab Royalties - Law360
Moderna, Inc. (MRNA) Issues Shareholder Letter Highlighting Strategic Developments - GuruFocus
Bayer Seeks Covid-Vaccine Royalties Over Crop-Technology Patent - Bloomberg Law News
UBS Downgrades Moderna (MRNA) Amid Revenue Concerns - GuruFocus
Moderna downgraded to neutral at UBS on questions over revenue growth - MSN
Moderna (NASDAQ:MRNA) Stock Price Up 8.6%Time to Buy? - MarketBeat
Moderna stock jumps nearly 11% after BofA target lift; flu vaccine filing in focus - TechStock²
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine - The Globe and Mail
Moderna jumps 10% as BofA hikes target price - breakingthenews.net
Moderna rallies after BofA raises its price target to $24 from $21 - Sherwood News
BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating - MarketScreener
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Record-Courier
Moderna stock price target raised to $24 from $21 at BofA Securities - Investing.com UK
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine - Bartlesville Examiner-Enterprise
Moderna reaffirms 2025-26 guidance, eyes multiple vaccine, oncology, and rare disease launches - Proactive financial news
Key facts: Moderna announces 2025 achievements; mRNA-1010 shows efficacy - TradingView — Track All Markets
CDC updates childhood vaccine schedule (PFE:NYSE) - Seeking Alpha
Jefferies reiterates Hold rating on Moderna stock, maintains $30 price target - Investing.com UK
Moderna, searching for a rebound, to seek approval of mRNA flu shot - BioPharma Dive
Moderna says aiming at 2025 projected revenue range of $1.6 bln to $2.0 bln - MarketScreener
Moderna (MRNA) Gains Ground Amid Flu Vaccine Regulatory Submissions - thebull.com.au
Moderna issues shareholder letter under Regulation FD disclosure - Investing.com
Moderna Highlights 2025 Progress and Strengthened Vaccine Portfolio - TipRanks
Moderna issues shareholder letter under Regulation FD disclosure By Investing.com - Investing.com South Africa
Moderna, Inc. Reports 2025 Achievements and 2026 Outlook - TradingView — Track All Markets
Moderna (MRNA) Advances Seasonal Flu Vaccine Regulatory Submissi - GuruFocus
Moderna (MRNA) Seeks Approval for New Influenza Vaccine - GuruFocus
Moderna (MRNA) Seeks Approval for New Flu Vaccine Targeting Olde - GuruFocus
Moderna seeks global approvals for flu shot - MSN
Moderna seeks global approvals for flu shot (MRNA:NASDAQ) - Seeking Alpha
Moderna files for approval of flu vaccine in four countries - StreetInsider
New mRNA flu shot from Moderna may better match evolving virus strains - Stock Titan
Moderna, Inc. (MRNA) Stock Analysis: Navigating a 19% Upside Potential Amidst Revenue Challenges - DirectorsTalk Interviews
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Alliance Review
Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound - Yahoo Finance
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):